Entrada Therapeutics (TRDA) said Monday it has received approval from the UK's Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee to launch a phase 1/2 multiple ascending dose trial of its experimental ENTR-601-45 treatment of Duchenne muscular dystrophy.
The clinical study covers patients with a confirmed mutation in the Duchenne muscular dystrophy gene amenable to exon 45 skipping.
Entrada said it is on course to begin the trial in Q3.
Duchenne muscular dystrophy causes skeletal and heart muscle weakness that quickly gets worse with time.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。